Effect of Citalopram on Endometriosis

Investigating the effect of Citalopram (selective serotonin reuptake inhibitor) on the symptoms of endometriosis patients under medical treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180211038692N2

Enrollment

Registered

2023-10-26

Start date

2023-11-03

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis

Interventions

Intervention 1: Intervention group: Patients use 1 tablet of Citalopram 20mg(Sobhan Company) and one tablet of Verogest 2 mg (Ati Pharmed Company) daily for up to 3 months continuously. Intervention

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Symptomatic patients with endometriosis under medical treatment age between 18 till 45 no desire for pregnancy

Exclusion criteria

Exclusion criteria: pregnancy lactation abnormal findings against endometriosis indication for surgery drug intolerance SSRIs contraindications

Design outcomes

Primary

Measure	Time frame
???????? ??????. Timepoint: Before and 3 months after treatment starting. Method of measurement: Visual analogous scale.;Dysmenorrhea. Timepoint: Before and 3 months after treatment starting. Method of measurement: Visual analogous scale.;Dyschezia. Timepoint: Visual analogous scale. Method of measurement: Visual analogous scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Reyhaneh.Hosseini

Tehran University of Medical Sciences

r-hosseini@tums.ac.ir+98 21 7771 9922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026